Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Rhea-AI Summary
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, has announced a temporary trading halt of its ordinary shares on Euronext Paris starting July 24, 2025, at 9:00 a.m. CEST. The suspension is related to the company's previously announced public offering of American Depositary Shares (ADS) in the United States.
The trading halt will allow for investor allocation confirmations and pricing announcement of the U.S. offering. Each ADS represents one ordinary share with a nominal value of €0.01. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST.
Positive
- Company pursuing U.S. market expansion through ADS offering
- Strategic move to access U.S. capital markets
Negative
- Temporary trading suspension may cause short-term market disruption
- Potential dilution for existing shareholders through ADS offering
News Market Reaction – ABVX
On the day this news was published, ABVX gained 586.00%, reflecting a significant positive market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -10.5% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $3.95B to the company's valuation, bringing the market cap to $4.62B at that time. Trading volume was elevated at 3.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share,
This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, July 24, 2025, at approximately 3:30 p.m. (CEST).
***
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contacts:
| Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878 |
***
Disclaimers
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FAQ
Why did Abivax (ABVX) halt trading on Euronext Paris on July 24, 2025?
When will Abivax (ABVX) resume trading on Euronext Paris?
What is the structure of Abivax's ADS offering in the United States?
What is Abivax's main business focus?
